DK1406898T3 - Substituerede piperazinforbindelser og anvendelse af disse som fedtsyreoxidationsinhibitorer - Google Patents

Substituerede piperazinforbindelser og anvendelse af disse som fedtsyreoxidationsinhibitorer

Info

Publication number
DK1406898T3
DK1406898T3 DK02756522T DK02756522T DK1406898T3 DK 1406898 T3 DK1406898 T3 DK 1406898T3 DK 02756522 T DK02756522 T DK 02756522T DK 02756522 T DK02756522 T DK 02756522T DK 1406898 T3 DK1406898 T3 DK 1406898T3
Authority
DK
Denmark
Prior art keywords
fatty acid
acid oxidation
oxidation inhibitors
substituted piperazine
angina
Prior art date
Application number
DK02756522T
Other languages
Danish (da)
English (en)
Inventor
Kevin Shenk
Elfatih Elzein
Jeff Zablocki
Kenneth Rehder
Prabha Ibrahim
Venkata Palle
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Application granted granted Critical
Publication of DK1406898T3 publication Critical patent/DK1406898T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Lubricants (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Paper (AREA)
  • Pyridine Compounds (AREA)
DK02756522T 2001-07-19 2002-07-18 Substituerede piperazinforbindelser og anvendelse af disse som fedtsyreoxidationsinhibitorer DK1406898T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30662101P 2001-07-19 2001-07-19
PCT/US2002/022897 WO2003008411A1 (fr) 2001-07-19 2002-07-18 Composes de piperazine substitues et leur utilisation en tant qu'inhibiteurs de l'oxydation d'acides gras

Publications (1)

Publication Number Publication Date
DK1406898T3 true DK1406898T3 (da) 2005-05-30

Family

ID=23186103

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02756522T DK1406898T3 (da) 2001-07-19 2002-07-18 Substituerede piperazinforbindelser og anvendelse af disse som fedtsyreoxidationsinhibitorer

Country Status (21)

Country Link
US (1) US6930111B2 (fr)
EP (1) EP1406898B1 (fr)
JP (1) JP2004537554A (fr)
KR (1) KR100919141B1 (fr)
CN (1) CN1533388A (fr)
AT (1) ATE292633T1 (fr)
AU (1) AU2008202958A1 (fr)
CA (1) CA2454059A1 (fr)
DE (1) DE60203623T2 (fr)
DK (1) DK1406898T3 (fr)
ES (1) ES2236557T3 (fr)
HU (1) HUP0402088A3 (fr)
IL (1) IL159897A0 (fr)
MX (1) MXPA04000565A (fr)
NO (1) NO327635B1 (fr)
NZ (1) NZ530705A (fr)
PL (1) PL368529A1 (fr)
PT (1) PT1406898E (fr)
RU (1) RU2300533C2 (fr)
WO (1) WO2003008411A1 (fr)
ZA (1) ZA200400404B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7001909B2 (en) * 2001-07-19 2006-02-21 Cv Therapeutics, Inc. Substituted heterocyclic compounds
AU2003248558B8 (en) * 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
WO2004014881A2 (fr) 2002-08-09 2004-02-19 Astra Zeneca Ab Nouveaux composes
TW200424183A (en) * 2002-08-09 2004-11-16 Nps Pharma Inc New compounds
US7074809B2 (en) 2002-08-09 2006-07-11 Astrazeneca Ab Compounds
EP1806346B1 (fr) * 2002-12-05 2009-07-22 Cv Therapeutics, Inc. Dérivés de Pipérazine substitués et leur utilisation comme inhibiteurs de l'oxydation d'acids gras
US7125876B2 (en) * 2002-12-05 2006-10-24 Cv Therapeutics, Inc. Substituted heterocyclic compounds
ATE443058T1 (de) 2003-01-03 2009-10-15 Cv Therapeutics Inc Substituierte heterozyklische verbindungen
KR20050092424A (ko) * 2003-01-17 2005-09-21 씨브이 쎄러퓨틱스, 인코포레이티드 심혈관 질환의 치료에 유용한 치환된 헤테로고리 화합물
WO2005000826A1 (fr) * 2003-06-23 2005-01-06 Cv Therapeutics, Inc. Derives d'uree de piperazines et de piperidines comme inhibiteurs de l'oxydation d'acides gras
WO2005061470A1 (fr) * 2003-12-18 2005-07-07 Cv Therapeutics, Inc. Composes piperazine et piperazine 1-akan-2-ol substitues
EP1699527A1 (fr) * 2004-01-02 2006-09-13 Advanced Cardiovascular Systems, Inc. Dispositifs medicaux revetus de lipoproteine a haute densite
WO2006029179A2 (fr) * 2004-09-08 2006-03-16 Cv Therapeutics, Inc. Composes heterocycliques substitues
CA2661538A1 (fr) 2006-08-24 2008-02-28 Wockhardt Research Centre Nouveaux macrolides et cetolides dotes d'une activite anti-microbienne
US8088920B2 (en) * 2008-03-31 2012-01-03 Hoffmann-La Roche Inc. 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents
WO2010042925A2 (fr) 2008-10-10 2010-04-15 Vm Discovery Inc. Compositions et méthodes pour traiter les troubles liés à la consommation d'alcool, la douleur et d'autres maladies
US20100292217A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
JPWO2011115150A1 (ja) * 2010-03-18 2013-07-04 興和株式会社 ベンゾチアジン化合物の製造方法
CN111285819A (zh) * 2018-12-07 2020-06-16 江苏恩华药业股份有限公司 一种苯并噁唑类化合物及其应用
WO2023023995A1 (fr) * 2021-08-25 2023-03-02 苏州大学 Médicament pour la prévention et le traitement d'une insuffisance cardiaque après une ischémie myocardique et application associée

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1133989A (en) 1964-12-08 1968-11-20 Chugai Pharmaceutical Co Ltd Theophylline derivatives, their salts and process for preparing the same
DE2834114A1 (de) * 1978-08-01 1980-02-14 Schering Ag Polyalkoxyphenylpyrrolidone iii, verfahren zu ihrer herstellung und ihre verwendung
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
JPS6137765A (ja) * 1984-07-19 1986-02-22 サンド・アクチエンゲゼルシヤフト ３‐アミノプロポキシアリール誘導体
US4723014A (en) * 1986-11-19 1988-02-02 Warner-Lambert Company Process for the preparation of 2-substituted-1,4-dihydropyridines
DE3723648A1 (de) * 1987-07-17 1989-01-26 Sandoz Ag Indol-derivate, ihre herstellung und sie enthaltende arzneimittel
JPH0699399B2 (ja) * 1988-10-06 1994-12-07 三井東圧化学株式会社 新規複素環化合物およびそれを有効成分として含有する製癌剤効果増強剤
JPH02268162A (ja) * 1989-04-10 1990-11-01 Fujisawa Pharmaceut Co Ltd ジフェニルピリジン誘導体
MX9308025A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
WO1998021190A1 (fr) * 1996-11-14 1998-05-22 American Home Products Corporation Tetrahydro-1,3,5-triazin-2[1h]-thiones substitues servant d'agents anti-atherosclereux
CA2382683A1 (fr) * 1999-09-13 2001-03-22 American Home Products Corporation Conjugues glucopyranosides de 2-(4-hydroxy-phenyl)-1-{4-(2-amin-1-yl-ethoxy)-benzyl|-1h-indol-5-ols
SE9904765D0 (sv) 1999-12-23 1999-12-23 Astra Ab Pharmaceutically-useful compounds
US6677343B2 (en) 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
US6552023B2 (en) 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
US6451798B2 (en) 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
EP1259493A2 (fr) 2000-02-22 2002-11-27 Cv Therapeutics, Inc. Composes de piperazine substitues
AU2001239827A1 (en) * 2000-02-22 2001-09-03 Cv Therapeutics, Inc. Substituted alkylene diamine compounds
SE0003795D0 (sv) * 2000-10-20 2000-10-20 Astrazeneca Ab Pharmaceutically useful compounds
US6573264B1 (en) 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives

Also Published As

Publication number Publication date
WO2003008411A1 (fr) 2003-01-30
EP1406898B1 (fr) 2005-04-06
NO20040234L (no) 2004-03-18
IL159897A0 (en) 2004-06-20
CA2454059A1 (fr) 2003-01-30
NZ530705A (en) 2005-08-26
RU2300533C2 (ru) 2007-06-10
HUP0402088A3 (en) 2010-03-29
US6930111B2 (en) 2005-08-16
EP1406898A1 (fr) 2004-04-14
HUP0402088A2 (hu) 2005-02-28
CN1533388A (zh) 2004-09-29
NO327635B1 (no) 2009-09-07
DE60203623D1 (de) 2005-05-12
ATE292633T1 (de) 2005-04-15
KR100919141B1 (ko) 2009-09-25
MXPA04000565A (es) 2005-06-17
JP2004537554A (ja) 2004-12-16
DE60203623T2 (de) 2006-01-19
PL368529A1 (en) 2005-04-04
ES2236557T3 (es) 2005-07-16
RU2004104951A (ru) 2005-06-27
AU2008202958A1 (en) 2008-07-31
HK1064374A1 (en) 2005-01-28
ZA200400404B (en) 2004-10-14
US20030181352A1 (en) 2003-09-25
PT1406898E (pt) 2005-08-31
KR20040029374A (ko) 2004-04-06
AU2002322527A2 (en) 2003-03-03
AU2002322527B2 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
DK1406898T3 (da) Substituerede piperazinforbindelser og anvendelse af disse som fedtsyreoxidationsinhibitorer
NO20054969L (no) 2-cyanopropansyreamid- og esterderivater og deres anvendelse
ATE411288T1 (de) Aryl-, aryloxy- und alkyloxysubstituierte 1h- indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
NO20053627L (no) Malonamidderivater som gamma-sekretase inhibitorer
NO20023879D0 (no) Partielle fettsyre-oksydasjonsinhibitorer i behandlingen av kongestiv hjertesvikt
BR0114045A (pt) Poliarilcarboxamidas úteis como agentes redutores de lipìdeos
NO20025665D0 (no) Serin-protease-inhibitorer
NO20051965L (no) Nye piperidinderivater for anvendelse ved behandling av kemokinmedierte sykdomstilstander.
CY1106969T1 (el) Αναστολεις dpp-iv
EA200401157A1 (ru) N-аминоацетилпирролидин-2-карбонитрилы и их применение в качестве ингибиторов ddp-iv
ATE311380T1 (de) Durch säuregruppen disubstitierte heteroaryl- derivate und ihre verwendung als matrix metalloproteinas inhibitoren
EA200200390A1 (ru) Новые оксабиспидиновые соединения, полезные при лечении сердечных аритмий
DK1569900T3 (da) Substituerede 3-carbonyl-1-yl-eddikesyrederivater som inhibitorer af plasminogenaktivator-inhibitor-1 (PAI-1)
SE0100326D0 (sv) New compounds
SE0101327D0 (sv) New crystalline forms
MXPA02012910A (es) Amidas de acidobifenilcarboxilico, su preparacion y su uso como medicinas.
DK1567502T3 (da) Substituerede dihydrophenantridinsulfonamider
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
NO20060314L (no) Nicotinamid-derivater anvendbare som PDE4-inhibitorer
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
NO20023001L (no) Substituerte piperazinderivater som MTP inhibitorer
ATE365737T1 (de) Substituierte piperazinverbindungen undderen verwendung als fettsuureoxidationsinhibitoren
UY27074A1 (es) Derivados de aminotriazolopiridina
WO2004067506A3 (fr) Composes heterocyclique substitues
DE60329323D1 (de) Substituierte heterozyklische verbindungen